 Singh worked closely with companies, international donors, and governments to develop sustainable, profitable business models for the production of life-saving medicines and diagnostics.He and his teams struck agreements with more than 20 companies in the U.S., India, China and Europe resulting in price reductions of up to 90%, nearly $1.5 billion in cost savings, and the development of more than 40 generic or new drug presentations.The work enabled 1.7 million more HIV-positive people to receive treatment, and supported access to advanced anti-malarial medicines for tens of millions.